Study of a new drug for mild Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study tests a new drug, QLH2405, for people with mild cognitive impairment or mild Alzheimer's disease. It aims to see if the drug is safe and how it affects memory and thinking.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 50 and 85 years old.
- You must have a diagnosis of mild cognitive impairment or mild Alzheimer's disease (confirmed by a doctor).
- You must have had memory or thinking problems for at least 6 months.
- You must have had a special brain scan (amyloid PET) that shows Alzheimer's-related changes.
- You must have a family member or caregiver who can come with you to all study visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well people with Alzheimer’s disease (AD) or mild cognitive impairment (MCI) perform on standardized memory/brain tests. It may help researchers understand changes over time, and whether certain types of brain signals or test results track with the condition.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This trial tests an investigational drug called Neuroaid II (MLC901) for people with mild to moderate Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
This study tests whether a new drug called Latrepirdine (DMB-I) is safe and effective for people with mild to moderate Alzheimer's dementia. It may help slow cognitive decline when added to current treatment or used alone.
Hear when a new Alzheimer's Disease(AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.